Drug-induced granulomatosis is dupilumab the new kid on the block?

N Belhomme (1) , T Gaignon (1) , S Jouneau (1, 2) , L Misery (3) , C Abasq-Thomas (3) , B Cador (1) , V Lecureur (2, 4) , S Cadiou (1) , A Ballerie (1, 2) , E Polard (1) , S Mensi (1) , P Jego (1, 2) , A Lescoat (1, 2)

1 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
2 Irset - Institut de recherche en santé, environnement et travail
3 CHU - BREST - Hôpital de la Cavale Blanche - CHRU Brest
4 EHESP - École des Hautes Études en Santé Publique [EHESP]

Dupilumab is an IgG4 antibody directed toward IL-4 and IL-13, two major effectors of the Th2 immunity response. It was originally developed for severe and/or refractory atopic dermatitis, nevertheless its use has secondarily been broadened to severe asthma . We report herein the case a 28-year-old, non-smoker male who presented to the emergency department with confusion, headaches, emesis and photophobia. His medical history included only a severe atopic dermatitis leading to dupilumab initation 4 months earlier. Physical examination revealed a meningoencephalitis syndrome, and a bilateral parotidomegaly.

Domaines: Sciences du Vivant [q-bio]; Dermatologie

N Belhomme, T Gaignon, S Jouneau, L Misery, C Abasq-Thomas, et al.. Drug-induced granulomatosis is dupilumab the new kid on the block?. Journal of the European Academy of Dermatology and Venereology, 2020, 34 (7), ⟨10.1111/jdv.16218⟩. ⟨hal-02470892⟩